Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for AMGN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AMGN and 80,000+ other tickers.
See exactly how AMGN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AMGN and 80,000+ other tickers.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid…
Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of waiting too long to disclose that it might owe the Internal Revenue Service $10.7 billion for underreporting six years of taxes.
Andra AP fonden cut its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,366 shares of the medical research company's stock after selling 11,734 shares during the quarter. Andra AP fonden's holdings in
On July 20, 2026, we present a DCF analysis for Amgen Inc (AMGN), a company that has shown strong price performance over the past year, with a 26.5% increase. T
Dimensional Fund Advisors LP lifted its position in shares of Amgen Inc. (NASDAQ: AMGN) by 2.3% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 3,304,344 shares of the medical research company's stock after buying an additional 73,365 shares during the period. Dimensional Fund Advisors LP
Boston Common Asset Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 10.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 29,640 shares of the medical research company's stock after selling 3,458 shares during the period. Boston Common Asset Management LLC's